50
Participants
Start Date
June 30, 2003
Primary Completion Date
April 30, 2007
Study Completion Date
January 31, 2012
Bevacizumab (drug), Herceptin (drug)
Suburban Hematology-Oncology Associates, P.A., Lawrenceville
Northwest Georgia Oncology Centers, P.C., Marietta
Northeast Georgia Cancer Care, LLC, Athens
Cancer Institute of Florida, P.A., Orlando
Oncology Hematology Associates of Central Illinois, P.C., Peoria
Comprehensive Cancer Centers of Nevada, Las Vegas
UCLA Medical Center, Los Angeles
Cancer Care Associates Medical Group, Inc., Redondo Beach
Pacific Shores Medical Group, Long Beach
North Valley Hematology/Oncology Medical Group, Northridge
Wilshire Oncology Medical Group, Inc., Pomona
Central Hematology Oncology Medical Group, Inc., Alhambra
San Diego Cancer Center, Vista
Virginia K. Crosson Cancer Center, Fullerton
Ventura County Hematology-Oncology Specialists, Oxnard
Sansum Santa Barbara Medical Foundation Clinic, Santa Barbara
Santa Barbara Hematology Oncology Medical Group, Inc., Santa Barbara
Comprehensive Blood and Cancer Center, Bakersfield
Collaborators (1)
Genentech, Inc.
INDUSTRY
Translational Oncology Research International
OTHER